Novartis-Regeneron Dispute Enters a New Phase

By Rich Kirkner | May 11, 2021

If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent…

Read More

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System

By Steve Lenier | April 28, 2021

Despite a potential business arrangement with a fellow retinal prosthesis innovator falling apart in recent weeks, Paris-based Pixium Vision is working to stay on course…

Read More

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

By Steve Lenier | April 20, 2021

Gyroscope Therapeutics recently raised $148 million in a Series C financing to advance the clinical development of GT005, its lead investigational gene therapy, which is…

Read More

Anterior Segment Advances That ‘Won’ 2020 and Those Poised To Disrupt the Future

By Conni Bergmann Koury | April 14, 2021

2020 was a challenging year for ophthalmic surgeons, but an array of device and pharma developments helped them get through it, while other advances are…

Read More

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol

By Conni Bergmann Koury | April 7, 2021

In another sign of the intense interest in the category of presbyopia-correcting drops, Visus Therapeutics raised $36 million in Series A financing that will be…

Read More

Aura Biosciences Takes Key Steps to Advance Lead Candidate

By Rich Kirkner | March 31, 2021

With a fresh infusion of capital and a new chief operating officer steeped in regulatory affairs, Aura Biosciences has put key pieces into place to…

Read More

Biomedical Informatics Helps Focus Director Dr. Michael Chiang’s Vision for NEI

By Rich Kirkner | March 23, 2021

Michael F. Chiang, MD, who took over as director of the National Eye Institute at the close of 2020, brings a unique background as an…

Read More

New Technology and Teamwork Are Key for Combining Forces

By Steve Lenier | March 16, 2021

Science and teamwork are important factors for companies considering acquisitions, collaborations, or partnerships in the dry eye space. That was the consensus of corporate leaders…

Read More

What’s a SPAC? A Route to Public Markets for Gemini Therapeutics

By Heather Johnson | March 3, 2021

Gemini Therapeutics, a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market…

Read More

Ocular Gene Therapy Takes Next Step Beyond Inherited Retinal Disease

By Rich Kirkner | February 23, 2021

Ten years from now, gene therapy for ocular disease will have made the shift from exclusively targeting inherited retinal diseases with very small populations, such…

Read More

With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds

By Heather Johnson | February 10, 2021

What a difference a few months makes. Outlook Therapeutics’ stock price plunged last August on the heels of top-line results from the NORSE 1 clinical…

Read More

Manufacturing Strategy Key to AGTC’s Next Steps for Gene Therapy Programs

By Rich Kirkner | August 18, 2020

As Applied Genetic Technologies Corp. takes the next steps in the development of its lead gene therapy candidate for inherited retinal disease, the company has…

Read More


Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.